Compare ONEW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | CCCC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.4M | 185.1M |
| IPO Year | 2019 | 2020 |
| Metric | ONEW | CCCC |
|---|---|---|
| Price | $9.50 | $2.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $16.75 | $12.20 |
| AVG Volume (30 Days) | 134.9K | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.27 | N/A |
| P/E Ratio | $3.72 | ★ N/A |
| Revenue Growth | ★ 5.62 | 1.02 |
| 52 Week Low | $9.01 | $1.09 |
| 52 Week High | $18.15 | $3.82 |
| Indicator | ONEW | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 31.85 | 53.55 |
| Support Level | N/A | $2.14 |
| Resistance Level | $12.51 | N/A |
| Average True Range (ATR) | 0.67 | 0.34 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 14.44 | 38.82 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.